Optimal management of elderly/old Ph+ acute lymphoblastic leukemia patients

Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is today a curable disease. In the real life, too many adult ALL patients are not adequately worked up at diagnosis and treated, and this occurs in particular in elderly/old individuals. We hereby discuss, through representative case descriptions, how Ph+ ALL patients diagnosed in their seventh, eight and nineth decade of life through a timely, accurate and personalized tyrosine kinase inhibitor (TKI) administration, in the absence of systemic chemotherapy, can experience long-lived responses, minimal residual disease negativity, and a good quality of life. To an extent that stopping TKI administration can also be considered. This perspective article represents a proof of concept that nowadays even in elderly/old Ph+ ALL the disease can be cured or kept under prolonged control if adequately managed.

Authors

Institutions

Publication Details

Journal
Haematologica
Published
2026-01-22
DOI
https://doi.org/10.3324/haematol.2025.300060
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimal management of elderly/old Ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Felicetto Ferrara, Robin Foà, Giovanni Pizzolo
Haematologica
Acute Lymphoblastic Leukemia research
article

Optimal management of elderly/old Ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Felicetto Ferrara, Robin Foà, Giovanni Pizzolo
article en

Abstract

Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) is today a curable disease. In the real life, too many adult ALL patients are not adequately worked up at diagnosis and treated, and this occurs in particular in elderly/old individuals. We hereby discuss, through representative case descriptions, how Ph+ ALL patients diagnosed in their seventh, eight and nineth decade of life through a timely, accurate and personalized tyrosine kinase inhibitor (TKI) administration, in the absence of systemic chemotherapy, can experience long-lived responses, minimal residual disease negativity, and a good quality of life. To an extent that stopping TKI administration can also be considered. This perspective article represents a proof of concept that nowadays even in elderly/old Ph+ ALL the disease can be cured or kept under prolonged control if adequately managed.

Haematologica
Ospedale Antonio Cardarelli (IT), Azienda Ospedaliera Universitaria Integrata Verona (IT), Sapienza University of Rome (IT)
Associazione Italiana per la Ricerca sul Cancro
Openalex Percentile: Top 82%
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.